Medpace Holdings, Inc. (NASDAQ:MEDP) Position Increased by Distillate Capital Partners LLC

Distillate Capital Partners LLC boosted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.7% in the fourth quarter, HoldingsChannel reports. The firm owned 44,317 shares of the company’s stock after purchasing an additional 1,155 shares during the quarter. Distillate Capital Partners LLC’s holdings in Medpace were worth $14,723,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Lindbrook Capital LLC lifted its stake in Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its holdings in shares of Medpace by 0.5% in the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock worth $1,789,000 after acquiring an additional 29 shares during the period. Assetmark Inc. lifted its position in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in Medpace by 4.1% during the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after purchasing an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. grew its position in Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after purchasing an additional 30 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MEDP. Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They set a “market perform” rating and a $330.00 price target on the stock. Leerink Partnrs raised Medpace to a “hold” rating in a research note on Monday, March 24th. Truist Financial reduced their price target on Medpace from $347.00 to $333.00 and set a “hold” rating for the company in a research report on Thursday. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Finally, Mizuho reduced their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a report on Wednesday. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $361.90.

Medpace Stock Up 5.5 %

NASDAQ:MEDP opened at $297.72 on Friday. The business’s 50-day moving average price is $323.58 and its 200 day moving average price is $334.41. Medpace Holdings, Inc. has a 52-week low of $272.00 and a 52-week high of $459.77. The firm has a market cap of $9.00 billion, a P/E ratio of 23.57, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.